# Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

> **NCT00749892** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Recurrent Bladder Urothelial Carcinoma
- Recurrent Renal Pelvis Urothelial Carcinoma
- Recurrent Ureter Urothelial Carcinoma
- Recurrent Urethral Urothelial Carcinoma
- Stage 0a Bladder Cancer AJCC v8
- Stage 0a Renal Pelvis Cancer AJCC v8
- Stage 0a Ureter Cancer AJCC v8
- Stage 0a Urethral Cancer AJCC v8
- Stage 0is Bladder Cancer AJCC v8
- Stage 0is Renal Pelvis Cancer AJCC v8
- Stage 0is Ureter Cancer AJCC v8
- Stage 0is Urethral Cancer AJCC v8
- Stage II Bladder Cancer AJCC v8
- Stage II Renal Pelvis Cancer AJCC v8
- Stage II Ureter Cancer AJCC v8
- Stage II Urethral Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8

## Interventions

- **DRUG:** Erlotinib Hydrochloride

## Key facts

- **NCT ID:** NCT00749892
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-10
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-11-26
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00749892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00749892, "Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00749892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*